MALAT-1联合PSA检测对前列腺癌的诊断价值-现代医学

MALAT-1联合PSA检测对前列腺癌的诊断价值

单位：洪湖市中医医院检验科, 湖北洪湖 433200

分类号：R737.25

出版年·卷·期（页码）：2018·46·第五期（487-492）

摘要：

目的：检测前列腺癌患者血清肺腺癌转移相关转录因子-1（MALAT-1）表达，探讨其对前列腺癌的诊断价值。方法：选择85例前列腺癌患者（癌变组）、68例良性前列腺增生患者（良性组）和50例男性健康体检者（对照组）作为研究对象，于术前、术后3 d、术后7 d采集癌变组和良性组患者空腹肘静脉血，于体检时采集对照组体检者空腹时静脉血；实时定量PCR检测血清MALAT-1表达，分析血清MALAT-1表达与前列腺癌患者临床参数的关系及其诊断价值。结果：癌变组血清MALAT-1相对表达量明显高于良性组和对照组，差异有统计学意义（P<0.01），但良性组和对照组血清MALAT-1相对表达差异无统计学意义（P>0.05）。与术前比较，良性组术后3 d、术后7 d血清MALAT-1表达无明显变化（P>0.05）；癌变组术后3 d血清MALAT-1相对表达较术前明显升高，差异有统计学意义（P<0.01）。临床分期>T2a组血清MALAT-1表达明显高于临床分期≤ T2a组（P<0.001）；Gleason评分>7分组血清MALAT-1表达明显高于Gleason评分≤ 7分组（P<0.001）；骨转移组血清MALAT-1表达明显高于无转移组（P<0.001）。血清MALAT-1表达与年龄、前列腺特异性抗原（PSA）浓度无关（P>0.05）。联合使用MALAT-1和PSA诊断前列腺癌的曲线下面积（0.865）高于单独使用MALAT-1（0.759）或PSA （0.800）；MALAT-1诊断PSA阴性（≤ 4 ng·ml^-1）前列腺癌的曲线下面积为0.747（95%置信区间为0.650~0.829），特异性为76.4%，敏感性为66.2%。结论：MALAT-1在前列腺癌中具有良好的诊断价值，可以作为前列腺癌非侵入性诊断的分子标志物。

Objective: To explore the expression of serum MALAT-1 in prostate cancer patients and its diagnostic value.Methods: A total of eighty-five prostate cancer patients, sixty-eight benign prostatic hyperplasia and fifty male healthy person were selected as cancer group, benign group and control group, respectively, the vein blood in the cancer group and the benign group was collected at pre-operation, 3-day post-operation and 7-day post-operation, respectively. Meanwhile, same volume of vein blood was collected in the control group. The serum levels of MALAT-1 was detected by quantitative real-time PCR, the correlation between MALAT-1 and patients clinical parameters, as well as its diagnostic value were analyzed.Results: The expression of serum MALAT-1 in the cancer group was significantly higher than in the benign group and the control group (P<0.01), however, there was no significant difference between the benign group and the control group (P>0.05). Compared with pre-operation, there were no changes of MALAT-1 expression at 3-day and 7-day post-operation in the benign group (P>0.05), but at 3-day post-operation, the expression of MALAT-1 was obviously increased in the cancer group when compared to the pre-operation (P<0.01). The expression of MALAT-1 in the T2a group was significantly higher than in the T2a group (P<0.001), the expression of MALAT-1 in the group Gleason scores>7 was significantly higher than in the group Gleason scores ≤ 7 (P<0.001), the expression of MALAT-1 in the bone metastases group was significantly higher than that in the without bone metastases group (P<0.001), there was no significant correlation between MALAT-1 and age, PSA (P>0.05). The area under curve of combined diagnostic of MALAT-1 and PSA (0.865) was higher than single MALAT-1 (0.759) or PSA (0.800). The AUC of MALAT-1 for PSA-negtive prostate cancer was 0.747 (95% CI:0.650-0.829), and the specificity and sensitivity were 76.4% and 66.2%, respectively.Conclusion: MALAT-1 has a good diagnostic value and can be used as a new non-invasive biomarker for the diagnosis of prostate cancer.

参考文献：

[1] VERMASSEN T,van PRAET C,VANDERSCHAEGHE D,et al.Capillary electrophoresis of urinary prostate glycoproteins assists in the diagnosis of prostate cancer[J].Electrophoresis,2014,35(7):1017-1024.
[2] STURZU A,KLOSE U,SHEIKH S,et al.The gastrin/cholecystokinin-B receptor on prostate cells-a novel target for bifunctional prostate cancer imaging[J].Eur J Pharm Sci,2014,52:69-76.
[3] GARRIDO-MEDINA R,FARINA-GOMEZ N,DIEZ-MASA J C,et al.Immunoaffinity chromatographic isolation of prostate-specific antigen from seminal plasma for capillary electrophoresis analysis of its isoforms[J].Anal Chim Acta,2014,820:47-55.
[4] BIRGANI M T,HAJJARI M,SHAHRISA A,et al.Long non-coding RNA SNHG6 as a potential biomarker for hepatocellular carcinoma[J].Pathol Oncol Res,2017,12(1):1-9.
[5] ZHU L,LIU J,MA S,et al.Long noncoding RNA MALAT-1 can predict metastasis and a poor prognosis:a meta-analysis[J].Pathol Oncol Res,2015,21(4):1259-1264.
[6] SCHMIDT L H,GöRLICH D,SPIEKER T,et al.Prognostic impact of Bcl-2 depends on tumor histology and expression of MALAT-1 lncRNA in non-small-cell lung cancer[J].J Thorac Oncol,2014,9(9):1294-1304.
[7] JIAO F,HU H,YUAN C,et al.Elevated expression level of long noncoding RNA MALAT-1 facilitates cell growth,migration and invasion in pancreatic cancer[J].Oncol Rep,2014,32(6):2485-2492.
[8] 石婷,高戈,曹颖丽,等.非小细胞肺癌患者血清中MALAT1表达水平及其临床意义[J].临床检验杂志,2016,34(2):114-117.
[9] REN S,WANG F,SHEN J,et al.Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancerJ].Eur J Cancer,2013,49(13):2949-2959.
[10] KAVOSI B,SALIMI A,HALLAJ R,et al.A highly sensitive prostate-specific antigen immunosensor based on gold nanoparticles/PAMAM dendrimer loaded on MWCNTS/chitosan/ionic liquid nanocomposite[J].Biosens Bioelectron,2014,52:20-28.
[11] KIM J H,LEE S W,KIM J H,et al.Association between obesity,prostate-specific antigen level and prostate-specific antigen density in men with a negative prostate biopsy[J].J Int Med Res,2014,42(3):821-827.
[12] 陈曦,莫林键,汪小明,等.Ⅲa型前列腺炎患者EPS中锌离子、PSA浓度变化及其临床意义[J].山东医药,2015,55(45):22-25.
[13] 谭思嘉,许露伟,徐郑,等.PHI/PCA3在前列腺癌早期诊断中的应用价值探讨[J].中华医学杂志,2016,96(2):100-103.
[14] 王佳鑫,段远胜,岳恺,等.MALAT1通过VHL/β-catenin通路影响口腔鳞状细胞癌生长侵袭的实验研究[J].中国肿瘤临床,2017,44(9):418-423.
[15] 季青,周宁,刘宣,等.MALAT1、COX-2、β-catenin、MMP-3、MMP-9等基因在结直肠癌发生发展中的意义[J].国际肿瘤学杂志,2012,39(6):477-480.
[16] 田智,刘亮华,廖江涛,等.长链非编码核糖核酸Malat-1、p21和GAS5在大肠癌组织中的表达及其诊断价值[J].华中科技大学学报(医学版),2017,46(1):10-14.
[17] 智能,李霞.血浆长链非编码RNA转移相关肺腺癌转录因子1对肺癌临床诊断价值[J].临床肺科杂志,2016,21(12):2154-2158.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录